British Journal of Pharmacology,
Journal Year:
2017,
Volume and Issue:
174(19), P. 3242 - 3256
Published: March 8, 2017
Learning
to
associate
cues
or
contexts
with
potential
threats
rewards
is
adaptive
and
enhances
survival.
Both
aversive
appetitive
memories
are
therefore
powerful
drivers
of
behaviour,
but
the
inappropriate
expression
conditioned
responding
fear‐
drug‐related
stimuli
can
develop
into
anxiety‐related
substance
abuse
disorders
respectively.
These
associated
abnormally
persistent
emotional
inadequate
treatment,
often
leading
symptom
relapse.
Studies
show
that
cannabidiol,
main
non‐psychotomimetic
phytocannabinoid
found
in
Cannabis
sativa
,
reduces
anxiety
via
5‐HT
1A
(indirect)
cannabinoid
receptor
activation
paradigms
assessing
innate
responses
threat.
There
also
accumulating
evidence
from
animal
studies
investigating
effects
cannabidiol
on
fear
memory
processing
indicating
it
learned
translationally
relevant
phobias
post‐traumatic
stress
disorder.
Cannabidiol
does
so
by
reducing
acutely
disrupting
reconsolidation
enhancing
extinction,
both
which
result
a
lasting
reduction
fear.
Recent
have
begun
elucidate
drug
using
translational
relevance
addiction.
The
findings
suggest
their
reconsolidation.
Here,
we
review
literature
demonstrating
anxiolytic
before
focusing
its
various
processes.
Understanding
how
regulates
emotion
may
eventually
lead
use
as
treatment
for
disorders.
Linked
Articles
This
article
part
themed
section
Pharmacology
Cognition:
Panacea
Neuropsychiatric
Disease?
To
view
other
articles
this
visit
http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.19/issuetoc
Journal of Clinical Medicine Research,
Journal Year:
2020,
Volume and Issue:
12(3), P. 129 - 141
Published: Jan. 1, 2020
Considering
data
from
in
vitro
and
vivo
studies,
cannabidiol
(CBD)
seems
to
be
a
promising
candidate
for
the
treatment
of
both
somatic
psychiatric
disorders.
The
aim
this
review
was
collect
dose(s),
dosage
schemes,
efficacy
safety
reports
CBD
use
adults
clinical
studies.
A
systematic
search
performed
PubMed,
Embase
Cochrane
library
articles
published
English
between
January
1,
2000
October
25,
2019.
terms
used
were
related
cannabis
adults.
We
identified
25
studies
(927
patients;
538
men
389
women),
which
22
controlled
trials
(833
patients)
three
observational
designs
(94
five
countries.
Formulations,
dose
schemes
varied
significantly
Varying
effects
randomized
(RCTs),
more
apparent
non-RCTs
minor
issues
general.
From
trials,
we
anxiolytic
with
acute
administration,
therapeutic
social
anxiety
disorder,
psychotic
disorder
substance
In
general,
heterogeneous
showed
substantial
risks
bias.
Although
results
have
been
identified,
considerable
variation
route
administration
employed
across
There
evidence
support
single
positive
effect
on
short
medium-term
symptomatic
improvement
schizophrenia
lack
cognitive
functioning
Overall,
well
tolerated
mild
side
effects.
J
Clin
Med
Res.
2020;12(3):129-141
doi:
https://doi.org/10.14740/jocmr4090
Molecules,
Journal Year:
2023,
Volume and Issue:
28(7), P. 3271 - 3271
Published: April 6, 2023
Cannabidiol
(CBD)
is
a
major
phytocannabinoid
present
in
Cannabis
sativa
(Linneo,
1753).
This
naturally
occurring
secondary
metabolite
does
not
induce
intoxication
or
exhibit
the
characteristic
profile
of
drugs
abuse
from
cannabis
like
Δ9-tetrahydrocannabinol
(∆9-THC)
does.
In
contrast
to
∆9-THC,
our
knowledge
neuro-molecular
mechanisms
CBD
limited,
and
its
pharmacology,
which
appears
be
complex,
has
yet
been
fully
elucidated.
The
study
pharmacological
effects
grown
exponentially
recent
years,
making
it
necessary
generate
frequently
updated
reports
on
this
important
metabolite.
article,
rationalized
integration
action
molecular
targets
implications
animal
models
human
diseases,
such
as
epilepsy,
pain,
neuropsychiatric
disorders,
Alzheimer’s
disease,
inflammatory
are
presented.
We
identify
around
56
different
for
CBD,
including
enzymes
ion
channels/metabotropic
receptors
involved
neurologic
conditions.
Herein,
we
compiled
found
scientific
literature
multiple
actions
CBD.
vitro
vivo
findings
essential
understanding
polypharmacological
nature
natural
product.
Anesthesia & Analgesia,
Journal Year:
2017,
Volume and Issue:
125(5), P. 1638 - 1652
Published: May 20, 2017
There
is
a
lack
of
consensus
on
the
role
selective
cannabinoids
for
treatment
neuropathic
pain
(NP).
Guidelines
from
national
and
international
societies
have
provided
contradictory
recommendations.
The
primary
objective
this
systematic
review
meta-analysis
(SR-MA)
was
to
determine
analgesic
efficacy
safety
compared
conventional
management
or
placebo
chronic
NP.We
reviewed
randomized
controlled
trials
that
(dronabinol,
nabilone,
nabiximols)
with
treatments
(eg,
pharmacotherapy,
physical
therapy,
combination
these)
in
patients
NP
because
may
be
any
these
therapies
none
if
all
standard
failed
provide
analgesia
been
associated
adverse
effects.
MEDLINE,
EMBASE,
other
major
databases
up
March
11,
2016,
were
searched.
Data
scores
numerical
rating
scale
its
subtypes,
central
peripheral,
meta-analyzed.
certainty
evidence
classified
using
Grade
Recommendations
Assessment,
Development,
Evaluation
approach.Eleven
including
1219
(614
cannabinoid
605
comparator
groups)
included
SR-MA.
variability
studies
quality
reporting,
etiology
NP,
type
dose
cannabinoids.
Patients
who
received
reported
significant,
but
clinically
small,
reduction
mean
(0-10
scale)
groups
(-0.65
points;
95%
confidence
interval,
-1.06
-0.23
P
=
.002,
I
60%;
Evaluation:
weak
recommendation
moderate-quality
evidence).
Use
also
improvements
life
sleep
no
effects.Selective
small
benefit
NP.
high
degree
heterogeneity
among
publications
Well-designed,
large,
are
required
better
evaluate
specific
dosage,
duration
intervention,
effect
intervention
psychologic
function.
British Journal of Pharmacology,
Journal Year:
2017,
Volume and Issue:
174(19), P. 3242 - 3256
Published: March 8, 2017
Learning
to
associate
cues
or
contexts
with
potential
threats
rewards
is
adaptive
and
enhances
survival.
Both
aversive
appetitive
memories
are
therefore
powerful
drivers
of
behaviour,
but
the
inappropriate
expression
conditioned
responding
fear‐
drug‐related
stimuli
can
develop
into
anxiety‐related
substance
abuse
disorders
respectively.
These
associated
abnormally
persistent
emotional
inadequate
treatment,
often
leading
symptom
relapse.
Studies
show
that
cannabidiol,
main
non‐psychotomimetic
phytocannabinoid
found
in
Cannabis
sativa
,
reduces
anxiety
via
5‐HT
1A
(indirect)
cannabinoid
receptor
activation
paradigms
assessing
innate
responses
threat.
There
also
accumulating
evidence
from
animal
studies
investigating
effects
cannabidiol
on
fear
memory
processing
indicating
it
learned
translationally
relevant
phobias
post‐traumatic
stress
disorder.
Cannabidiol
does
so
by
reducing
acutely
disrupting
reconsolidation
enhancing
extinction,
both
which
result
a
lasting
reduction
fear.
Recent
have
begun
elucidate
drug
using
translational
relevance
addiction.
The
findings
suggest
their
reconsolidation.
Here,
we
review
literature
demonstrating
anxiolytic
before
focusing
its
various
processes.
Understanding
how
regulates
emotion
may
eventually
lead
use
as
treatment
for
disorders.
Linked
Articles
This
article
part
themed
section
Pharmacology
Cognition:
Panacea
Neuropsychiatric
Disease?
To
view
other
articles
this
visit
http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.19/issuetoc
